Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2001 1
2002 4
2003 3
2004 3
2005 5
2006 4
2007 6
2008 12
2009 31
2010 36
2011 31
2012 42
2013 37
2014 29
2015 24
2016 17
2017 10
2018 19
2019 17
2020 10
2021 21
2022 26
2023 15
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

348 results

Results by year

Filters applied: . Clear all
Page 1
Cannabidiol for the treatment of autism spectrum disorder: hope or hype?
Pedrazzi JFC, Ferreira FR, Silva-Amaral D, Lima DA, Hallak JEC, Zuardi AW, Del-Bel EA, Guimarães FS, Costa KCM, Campos AC, Crippa ACS, Crippa JAS. Pedrazzi JFC, et al. Among authors: crippa jas. Psychopharmacology (Berl). 2022 Sep;239(9):2713-2734. doi: 10.1007/s00213-022-06196-4. Epub 2022 Jul 29. Psychopharmacology (Berl). 2022. PMID: 35904579 Review.
Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report.
Crippa JA, Derenusson GN, Ferrari TB, Wichert-Ana L, Duran FL, Martin-Santos R, Simões MV, Bhattacharyya S, Fusar-Poli P, Atakan Z, Santos Filho A, Freitas-Ferrari MC, McGuire PK, Zuardi AW, Busatto GF, Hallak JE. Crippa JA, et al. J Psychopharmacol. 2011 Jan;25(1):121-30. doi: 10.1177/0269881110379283. Epub 2010 Sep 9. J Psychopharmacol. 2011. PMID: 20829306 Clinical Trial.
Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients.
Bergamaschi MM, Queiroz RH, Chagas MH, de Oliveira DC, De Martinis BS, Kapczinski F, Quevedo J, Roesler R, Schröder N, Nardi AE, Martín-Santos R, Hallak JE, Zuardi AW, Crippa JA. Bergamaschi MM, et al. Among authors: crippa ja. Neuropsychopharmacology. 2011 May;36(6):1219-26. doi: 10.1038/npp.2011.6. Epub 2011 Feb 9. Neuropsychopharmacology. 2011. PMID: 21307846 Free PMC article. Clinical Trial.
Phytocannabinoids and epilepsy.
dos Santos RG, Hallak JE, Leite JP, Zuardi AW, Crippa JA. dos Santos RG, et al. Among authors: crippa ja. J Clin Pharm Ther. 2015 Apr;40(2):135-43. doi: 10.1111/jcpt.12235. Epub 2014 Dec 4. J Clin Pharm Ther. 2015. PMID: 25475762 Review.
Clinical issues in cannabis use.
Bonomo Y, Souza JDS, Jackson A, Crippa JAS, Solowij N. Bonomo Y, et al. Among authors: crippa jas. Br J Clin Pharmacol. 2018 Nov;84(11):2495-2498. doi: 10.1111/bcp.13703. Epub 2018 Aug 17. Br J Clin Pharmacol. 2018. PMID: 29968386 Free PMC article. Review.
Letter to the Editor.
dos Santos RG, Osório FL, Crippa JA, Bouso JC, Hallak JE. dos Santos RG, et al. Among authors: crippa ja. J Forensic Leg Med. 2016 Feb;38:116-7. doi: 10.1016/j.jflm.2015.11.009. Epub 2015 Nov 23. J Forensic Leg Med. 2016. PMID: 26851679 Free article. No abstract available.
348 results